TrialDiabetes care2024

Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.

Ildiko Lingvay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.